CA3219090A1 - Preparation containing cyclic peptide compound and method for producing same - Google Patents
Preparation containing cyclic peptide compound and method for producing same Download PDFInfo
- Publication number
- CA3219090A1 CA3219090A1 CA3219090A CA3219090A CA3219090A1 CA 3219090 A1 CA3219090 A1 CA 3219090A1 CA 3219090 A CA3219090 A CA 3219090A CA 3219090 A CA3219090 A CA 3219090A CA 3219090 A1 CA3219090 A1 CA 3219090A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formulation
- composition according
- added
- mixed solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-079015 | 2021-05-07 | ||
| JP2021079015 | 2021-05-07 | ||
| PCT/JP2022/019540 WO2022234850A1 (ja) | 2021-05-07 | 2022-05-06 | 環状ペプチド化合物を含む製剤及びその製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3219090A1 true CA3219090A1 (en) | 2022-11-10 |
Family
ID=83932759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3219090A Pending CA3219090A1 (en) | 2021-05-07 | 2022-05-06 | Preparation containing cyclic peptide compound and method for producing same |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240366711A1 (https=) |
| EP (1) | EP4299069A4 (https=) |
| JP (2) | JP7181442B1 (https=) |
| KR (2) | KR20230169093A (https=) |
| CN (1) | CN117241817A (https=) |
| AU (1) | AU2022270498A1 (https=) |
| BR (1) | BR112023019622A2 (https=) |
| CA (1) | CA3219090A1 (https=) |
| IL (1) | IL306018A (https=) |
| MX (1) | MX2023013099A (https=) |
| TW (1) | TW202308679A (https=) |
| WO (1) | WO2022234850A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI787670B (zh) | 2011-12-28 | 2022-12-21 | 日商中外製藥股份有限公司 | 具有環狀部之胜肽化合物及其醫藥組成物 |
| PE20221323A1 (es) | 2019-11-07 | 2022-09-09 | Chugai Pharmaceutical Co Ltd | Compuesto de peptidos ciclicos que tiene accion inhibidora de kras |
| TW202309065A (zh) | 2021-05-07 | 2023-03-01 | 日商中外製藥股份有限公司 | 包含n-取代胺基酸殘基之環狀化合物的製造方法 |
| CA3256645A1 (en) | 2022-05-06 | 2025-04-23 | Chugai Seiyaku Kabushiki Kaisha | CYCLIC COMPOUND HAVING A SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS |
| EP4585605A1 (en) * | 2022-10-20 | 2025-07-16 | Chugai Seiyaku Kabushiki Kaisha | Method for producing cyclic peptide crystals |
| JPWO2024219480A1 (https=) * | 2023-04-20 | 2024-10-24 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2501219A (en) * | 2011-02-04 | 2013-10-16 | Aegis Therapeutics Llc | Orally bioavailable peptide drug compositions and methods thereof |
| JP6239979B2 (ja) | 2011-03-04 | 2017-11-29 | ニューヨーク・ユニバーシティ | Ｒａｓの調節因子としての水素結合代替大環状分子 |
| TWI787670B (zh) | 2011-12-28 | 2022-12-21 | 日商中外製藥股份有限公司 | 具有環狀部之胜肽化合物及其醫藥組成物 |
| EP3881829A1 (en) | 2014-11-07 | 2021-09-22 | Sublimity Therapeutics Limited | Compositions comprising cyclosporin |
| US10954287B2 (en) | 2016-04-15 | 2021-03-23 | Ra Pharmaceuticals, Inc. | Ras binding peptides and methods of use |
| WO2018031730A2 (en) | 2016-08-11 | 2018-02-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Peptide inhibitors of phosphoglycerate mutase and methods of use |
| JP7232758B2 (ja) | 2017-06-09 | 2023-03-06 | 中外製薬株式会社 | 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ |
| WO2020122182A1 (ja) | 2018-12-12 | 2020-06-18 | 中外製薬株式会社 | 分子内水素結合可能な官能基を有するアミノ酸とそれらのアミノ酸を含むペプチド化合物、およびそれらの製造方法 |
| PE20221323A1 (es) * | 2019-11-07 | 2022-09-09 | Chugai Pharmaceutical Co Ltd | Compuesto de peptidos ciclicos que tiene accion inhibidora de kras |
| TW202309065A (zh) * | 2021-05-07 | 2023-03-01 | 日商中外製藥股份有限公司 | 包含n-取代胺基酸殘基之環狀化合物的製造方法 |
-
2022
- 2022-05-06 AU AU2022270498A patent/AU2022270498A1/en not_active Abandoned
- 2022-05-06 WO PCT/JP2022/019540 patent/WO2022234850A1/ja not_active Ceased
- 2022-05-06 US US18/289,392 patent/US20240366711A1/en active Pending
- 2022-05-06 IL IL306018A patent/IL306018A/en unknown
- 2022-05-06 TW TW111117094A patent/TW202308679A/zh unknown
- 2022-05-06 JP JP2022548967A patent/JP7181442B1/ja active Active
- 2022-05-06 EP EP22798954.8A patent/EP4299069A4/en not_active Withdrawn
- 2022-05-06 MX MX2023013099A patent/MX2023013099A/es unknown
- 2022-05-06 KR KR1020237032063A patent/KR20230169093A/ko not_active Withdrawn
- 2022-05-06 KR KR1020237001877A patent/KR102582225B1/ko active Active
- 2022-05-06 BR BR112023019622A patent/BR112023019622A2/pt unknown
- 2022-05-06 CN CN202280029838.6A patent/CN117241817A/zh active Pending
- 2022-05-06 CA CA3219090A patent/CA3219090A1/en active Pending
- 2022-11-17 JP JP2022184220A patent/JP2023015334A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230020548A (ko) | 2023-02-10 |
| KR20230169093A (ko) | 2023-12-15 |
| WO2022234850A1 (ja) | 2022-11-10 |
| IL306018A (en) | 2023-11-01 |
| EP4299069A4 (en) | 2025-03-05 |
| JP7181442B1 (ja) | 2022-11-30 |
| CN117241817A (zh) | 2023-12-15 |
| US20240366711A1 (en) | 2024-11-07 |
| EP4299069A1 (en) | 2024-01-03 |
| JP2023015334A (ja) | 2023-01-31 |
| BR112023019622A2 (pt) | 2023-11-14 |
| AU2022270498A1 (en) | 2023-10-05 |
| TW202308679A (zh) | 2023-03-01 |
| MX2023013099A (es) | 2023-11-17 |
| JPWO2022234850A1 (https=) | 2022-11-10 |
| KR102582225B1 (ko) | 2023-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3219090A1 (en) | Preparation containing cyclic peptide compound and method for producing same | |
| TWI516263B (zh) | 經取代之５－氟－１ｈ－吡唑并吡啶類及其用途 | |
| ES2929526T3 (es) | Sal cristalina de L-arginina del ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para su uso en trastornos asociados al receptor S1P1 | |
| EP4031133B1 (en) | Pyruvate kinase r (pkr) activating compositions | |
| EP4663198A1 (en) | Composition containing cyclic peptide compound and surfactant | |
| EP3081557A1 (en) | Salt and solvates of a tetrahydroisoquinoline derivative | |
| US10370406B2 (en) | Salts and polymorphs of SCY-078 | |
| KR20240128984A (ko) | 전달에 사용되는 지질 및 조성물 | |
| EA027869B1 (ru) | Стабилизированная композиция такролимуса | |
| JP2021522306A (ja) | ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形 | |
| EP4406546A1 (en) | Composition containing peptide compound for use with surfactant | |
| US20190016733A1 (en) | Crystalline forms of thienopyrimidine compound | |
| WO2025040810A1 (en) | Therapeutic compounds, a method of manufacturing thereof as well as uses thereof | |
| EA049912B1 (ru) | Препарат, содержащий циклическое пептидное соединение, и способы его приготовления | |
| HK40096081A (zh) | 包含环状胜肽化合物的制剂及其制备方法 | |
| US10828265B2 (en) | Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery | |
| Dong et al. | Synthesis, characterization and in vitro release performance of the pegylated valnemulin prodrug | |
| CA3218470A1 (en) | Polymorph of imidazolidinone compound, preparation method therefor and use thereof | |
| JP2007512333A (ja) | 縮合ピロロカルバゾール含有粒子形成組成物 | |
| WO2023241552A1 (en) | Salt and/or crystal form for compounds as casein kinase inhibitors | |
| CN113372332B (zh) | 一种奥希替尼新晶型 | |
| HK40079381A (en) | Novel salts and polymorphs of scy-078 | |
| WO2025235577A1 (en) | Forms and formulations of substituted 3-((3-amino)piperidine-2,6-dione compounds | |
| HK40078162B (en) | Pyruvate kinase r (pkr) activating compositions | |
| AU2024328199A1 (en) | Therapeutic compounds, a method of manufacturing thereof as well as uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250407 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250407 |